OUR VISION

radically improved outcomes by addressing unmet needs in oncology and neurofibromatosis

OS2966

first-in-class antibody with multiple mechanisms of action. Dramatic preclinical efficacy in aggressive therapy-resistant cancers including recurrent glioblastoma.

OS342

innovative non-surgical treatment for dermal neurofibromas.

left_arrow
right_arrow